Cargando…

A Pragmatic Study of Basal and Mid-Mixture Insulins as Starter Insulins in Chinese Patients With Type 2 Diabetes: Observations From Long-Term, Real-World Experience

INTRODUCTION: According to Chinese guidelines, basal insulin (BI) or premixed insulins are recommended insulin starters following the failure of oral antihyperglycemic medication (OAM) in Chinese patients with type 2 diabetes (T2D). This pragmatic study investigated the long-term effectiveness, safe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Tianshu, Yuan, Huijuan, Ren, Jiangong, Li, Yuanyuan, Hou, Jianing, Du, Liying, Zhu, Jiankun, Chen, Lulu, Ji, Linong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947078/ https://www.ncbi.nlm.nih.gov/pubmed/33616875 http://dx.doi.org/10.1007/s13300-021-01007-z

Ejemplares similares

A pragmatic study of mid‐mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real‐world experience
por: Zhang, Xiaomei, et al.
Publicado: (2020)

First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia
por: TSAI, Shih-Tzer, et al.
Publicado: (2011)

Where to Initiate Basal Insulin Therapy: Inpatient or Outpatient Department? Real-World Observation in China
por: Chen, Minyuan, et al.
Publicado: (2022)

Impact of diet on the efficacy of insulin lispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes: Subgroup analysis of the Comparison Between Low Mixed Insulin and Mid Mixed Insulin as Starter Insulin For Patients with Type 2 Diabetes Mellitus (CLASSIFY Study) randomized trial
por: Chen, Wei, et al.
Publicado: (2016)

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study
por: Peng, Xuejun Victor, et al.
Publicado: (2020)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
por: Ponzani, Paola, et al.
Publicado: (2019)

A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures
por: Bonafede, Machaon MK, et al.
Publicado: (2010)

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016)

Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
por: Pantalone, Kevin M., et al.
Publicado: (2023)

Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study
por: Bellido, Diego, et al.
Publicado: (2018)

Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
por: Giugliano, Dario, et al.
Publicado: (2021)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting
por: Meneghini, Luigi F., et al.
Publicado: (2019)

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Insulin Injection Technique in China Compared with the Rest of the World
por: Song, Zhenqiang, et al.
Publicado: (2018)

Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
por: Blonde, Lawrence, et al.
Publicado: (2018)

Factors and outcomes associated with discontinuation of basal insulin therapy in patients with type 2 diabetes mellitus
por: Zhang, Puhong, et al.
Publicado: (2020)

Future of newer basal insulin
por: Madhu, S. V., et al.
Publicado: (2013)

Cardiovascular effects of basal insulins
por: Mannucci, Edoardo, et al.
Publicado: (2015)

Basal insulin titration by the app
por: Vangoitsenhoven, Roman, et al.
Publicado: (2023)

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
por: Oya, Junko, et al.
Publicado: (2021)

Insulin glargine 300 U/mL versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real‐life clinical trial
por: Meneghini, Luigi, et al.
Publicado: (2020)

Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study
por: Ragonese, Mauro, et al.
Publicado: (2020)

Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study
por: Mathiesen, Elisabeth R., et al.
Publicado: (2021)

Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting
por: Zhou, Fang L., et al.
Publicado: (2019)

Real-World Application of Insulin Pump Therapy Among Patients With Type 1 Diabetes in China: A Cross-Sectional Study
por: Huo, Lili, et al.
Publicado: (2022)

Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study
por: Harris, Stewart B., et al.
Publicado: (2021)

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs
por: Wei, Wenhui, et al.
Publicado: (2014)

Evaluating Glycemic Control in Patients with Type 2 Diabetes Suboptimally Controlled on Basal Insulin: UK ATTAIN Real-World Study
por: Jude, Edward B., et al.
Publicado: (2019)

Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real‐world data
por: Peng, Ying, et al.
Publicado: (2022)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Koji Starter and Koji World in Japan
por: Yamashita, Hideyuki
Publicado: (2021)

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study
por: Pettus, Jeremy, et al.
Publicado: (2019)

Against pragmatism: on efficacy, effectiveness and the real world
por: Kent, David M, et al.
Publicado: (2009)

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
por: Tinahones, F J, et al.
Publicado: (2014)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
por: Kalra, Sanjay, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_eo1icg1qecfdl3n2dltkupbkj6